Publication:
Mucormycosis in the COVID-19 Environment: A Multifaceted Complication

Simple item page
dc.contributor.authorSharma, Rohit
dc.contributor.authorKumar, Praveen
dc.contributor.authorRauf, Abdur
dc.contributor.authorChaudhary, Ashun
dc.contributor.authorPrajapati, Pradeep Kumar
dc.contributor.authorEmran, Talha Bin
dc.contributor.authorGon�alves Lima, Clara Mariana
dc.contributor.authorConte-Junior, Carlos Adam
dc.date.accessioned2025-01-27T09:57:11Z
dc.date.available2025-01-27T09:57:11Z
dc.date.issued2022
dc.description.abstractThe second wave of coronavirus disease 2019 (COVID-19) caused severe infections with high mortality. An increase in the cases of COVID-19-associated mucormycosis (CAM) was reported predominantly in India. Commonly present in immunocompromised individuals, mucormycosis is often a life-threatening condition. Confounding factors and molecular mechanisms associated with CAM are still not well understood, and there is a need for careful research in this direction. In this review, a brief account of the diagnosis, management, and advancement in drug discovery for mucormycosis has been provided. Here, we summarize major factors that dictate the occurrence of mucormycosis in COVID-19 patients through the analysis of published literature and case reports. Major predisposing factors to mucormycosis appear to be uncontrolled diabetes, steroid therapy, and certain cancers. At the molecular level, increased levels of iron in COVID-19 might contribute to mucormycosis. We have also discussed the potential role and regulation of iron metabolism in COVID-19 patients in establishing fungal growth. Other factors including diabetes prevalence and fungal spore burden in India as contributing factors have also been discussed. Copyright � 2022 Sharma, Kumar, Rauf, Chaudhary, Prajapati, Emran, Gon�alves Lima and Conte-Junior.
dc.identifier.doihttps://doi.org/10.3389/fcimb.2022.937481
dc.identifier.issn22352988
dc.identifier.urihttps://dl.bhu.ac.in/ir/handle/123456789/13527
dc.publisherFrontiers Media S.A.
dc.subjectamphotericin-B
dc.subjectCOVID-19
dc.subjectdiabetes
dc.subjectGRP78
dc.subjecthepcidin
dc.subjectmucormycosis
dc.subjectSARS-CoV-2
dc.subjectsteroids
dc.titleMucormycosis in the COVID-19 Environment: A Multifaceted Complication
dc.typeReview
dspace.entity.typePublication
journal.titleFrontiers in Cellular and Infection Microbiology
journalvolume.identifier.volume12

Files

Collections

2022